PY2031844A - Compuestos y métodos que inhiben eif4e - Google Patents

Compuestos y métodos que inhiben eif4e

Info

Publication number
PY2031844A
PY2031844A PY202002031844A PY2031844A PY2031844A PY 2031844 A PY2031844 A PY 2031844A PY 202002031844 A PY202002031844 A PY 202002031844A PY 2031844 A PY2031844 A PY 2031844A PY 2031844 A PY2031844 A PY 2031844A
Authority
PY
Paraguay
Prior art keywords
sup
compounds
methods
formula
pharmaceutically acceptable
Prior art date
Application number
PY202002031844A
Other languages
English (en)
Spanish (es)
Inventor
Gruus Alan
X Xiang Alan
Viet Tran Chinh
Nilewski Christian
Kenneth Garrick
T Ernt Justin
Urkalan Kaveri
Shaghafi Mike
A Sprengeler Paul
Spery Samuel
H Reich Siegfried
MUKAIYAMA Takasuke
Michels Theo
Original Assignee
Effector Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Effector Therapeutics Inc filed Critical Effector Therapeutics Inc
Publication of PY2031844A publication Critical patent/PY2031844A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PY202002031844A 2019-07-02 2020-07-02 Compuestos y métodos que inhiben eif4e PY2031844A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962869662P 2019-07-02 2019-07-02

Publications (1)

Publication Number Publication Date
PY2031844A true PY2031844A (es) 2021-04-19

Family

ID=71614984

Family Applications (1)

Application Number Title Priority Date Filing Date
PY202002031844A PY2031844A (es) 2019-07-02 2020-07-02 Compuestos y métodos que inhiben eif4e

Country Status (15)

Country Link
US (2) US11286268B1 (cg-RX-API-DMAC10.html)
EP (1) EP3994139A1 (cg-RX-API-DMAC10.html)
JP (1) JP7595055B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220061945A (cg-RX-API-DMAC10.html)
CN (1) CN114269756B (cg-RX-API-DMAC10.html)
AR (1) AR119339A1 (cg-RX-API-DMAC10.html)
AU (1) AU2020299362B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021026682A2 (cg-RX-API-DMAC10.html)
CA (2) CA3188446A1 (cg-RX-API-DMAC10.html)
CL (1) CL2021003573A1 (cg-RX-API-DMAC10.html)
IL (1) IL289456A (cg-RX-API-DMAC10.html)
PY (1) PY2031844A (cg-RX-API-DMAC10.html)
TW (1) TWI748541B (cg-RX-API-DMAC10.html)
UY (1) UY38773A (cg-RX-API-DMAC10.html)
WO (1) WO2021003157A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220378821A1 (en) * 2019-07-02 2022-12-01 Effector Therapeutics, Inc. Methods of treating braf-mutated cancer cells
EP4076438A4 (en) * 2019-12-18 2023-11-29 Merck Sharp & Dohme LLC BICYCLIC HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HERPES VIRUSES
WO2021240337A1 (en) * 2020-05-27 2021-12-02 Effector Therapeutics, Inc. Covalent modifiers of eif4e inhibiting compounds
KR20230124648A (ko) * 2020-12-22 2023-08-25 화이자 인코포레이티드 Eif4e 억제제의 고체 형태
EP4430029A4 (en) * 2021-11-09 2025-09-10 Vigil Neuroscience Inc HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL AGONISTS 2 AND METHODS OF USE
AU2023375677A1 (en) * 2022-11-10 2025-06-05 Ribometrix, Inc. COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF
TW202428278A (zh) * 2022-12-23 2024-07-16 大陸商南京聖和藥業股份有限公司 作為eIF4E抑制劑的化合物及其應用
IL326137A (en) 2023-07-28 2026-03-01 Cogent Biosciences Inc PI3K inhibitors
WO2025101516A1 (en) * 2023-11-06 2025-05-15 Ribometrix, Inc. Methods of using eif4e inhibitors for treating cancer
WO2025120599A1 (en) * 2023-12-08 2025-06-12 Ribometrix, Inc. METHODS OF USING eIF4E INHIBITORS FOR TREATING CANCER

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255161A1 (en) 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
CA2724426A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
US9540371B2 (en) 2013-04-29 2017-01-10 Vanderbilt University Substituted quinazolin-4(3H)-ones, pyrido[3,4-d]pyrimidin-4(3H)-ones, pyrido[3,2-d]pyrimidin-4(3H)-ones and pyrido[2,3-d]pyrimidin-4(3H)-ones as positive allosteric modulators of muscarinic acetycholine receptor M1
JP2017510552A (ja) 2014-02-07 2017-04-13 イーフェクター セラピューティクス, インコーポレイテッド 線維性疾患を治療するための方法
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 MnK抑制劑及其相關方法

Also Published As

Publication number Publication date
CA3188446A1 (en) 2021-01-07
JP7595055B2 (ja) 2024-12-05
US20230108594A1 (en) 2023-04-06
CN114269756A (zh) 2022-04-01
CA3085255A1 (en) 2021-01-02
TW202115058A (zh) 2021-04-16
AR119339A1 (es) 2021-12-09
KR20220061945A (ko) 2022-05-13
TWI748541B (zh) 2021-12-01
WO2021003157A1 (en) 2021-01-07
UY38773A (es) 2021-01-29
AU2020299362A1 (en) 2022-02-24
IL289456A (en) 2022-02-01
US11286268B1 (en) 2022-03-29
AU2020299362B2 (en) 2026-02-26
CL2021003573A1 (es) 2022-08-12
BR112021026682A2 (pt) 2022-03-15
EP3994139A1 (en) 2022-05-11
JP2022539256A (ja) 2022-09-07
CN114269756B (zh) 2024-05-14

Similar Documents

Publication Publication Date Title
CL2021003573A1 (es) Compuestos y métodos que inhiben eif4e
MX383051B (es) Compuestos que inhiben eif4a y métodos relacionados a los mismos.
CO2022008997A2 (es) Compuestos tricíclicos sustituidos
SA522433155B1 (ar) مركبات ثلاثية الحلقة مستبدلة
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
CU24627B1 (es) Derivados de imidazolidin-2-ona sustituidos como inhibidores de prmt5
MX2021011389A (es) Compuestos de imidazolonilquinolina y usos terapeuticos de los mismos.
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
CL2017001017A1 (es) Nuevos compuestos de metil-piperidina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
MX375323B (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos.
CO2017009891A2 (es) Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta)
CL2020002562A1 (es) (divisional de solicitud 1097-2020) derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
NI201400031A (es) Derivados de ( 4 - fenilimidazol - 2 - il ) etilamina útiles como moduladores de canal de sodio
MX379459B (es) Inhibidores de bromodominios.
UY33491A (es) ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?.
CO6531444A2 (es) Métodos sintéticos para compuestos espiro-oxoindol
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
SA521430330B1 (ar) Eed و rc2 مشتقات آزولوبيريدين كبيرة الحلقة كمعدلات
CO2020004669A2 (es) Derivados de bencimidazol y sus usos
CU20190042A7 (es) Compuestos derivados de naftiridinona
UY37225A (es) Inhibidores del potenciador del homólogo zeste 2 campo de la invención
MX2017011978A (es) Analogos deuterados de etifoxina, sus derivados y usos de estos.
AR104731A1 (es) Benzamidas sustituidas y métodos para utilizarlas
CR20210014A (es) Derivados de pirrolo [1,2-b] piridazina